{"commentary":{"count":46,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":20,"x_thread":16,"podcast":7,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04285086\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SURPASS ET","nct_id":"NCT04285086","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=surpass-et-nct04285086. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SURPASS ET","arms":[{"description":"Pre-filled Syringe, Q2W, SC injection","label":"Ropeginterferon alfa-2b (P1101)","type":"EXPERIMENTAL"},{"description":"Capsules, Daily, p.o.","label":"Anagrelide","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"conditions":["Essential Thrombocythemia"],"enrollment":{"count":174,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ropeginterferon alfa-2b","type":"BIOLOGICAL"},{"name":"Anagrelide","type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"PharmaEssentia","official_title":"A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-11-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Peripheral blood count remission","timeFrame":"month 9 and month 12"},{"measure":"Improvement or non-progression in disease-related signs","timeFrame":"month 9 and month 12"},{"measure":"Large symptoms improvement or maintain non-progression","timeFrame":"month 9 and month 12"},{"measure":"Absence of hemorrhagic or thrombotic events","timeFrame":"month 9 and month 12"}],"references":[{"citation":"Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L; SURPASS-ET Study Group. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025 Nov;12(11):e862-e875. doi: 10.1016/S2352-3026(25)00264-9.","pmid":"41193116","type":"DERIVED"},{"citation":"Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep;18(27):2999-3009. doi: 10.2217/fon-2022-0596. Epub 2022 Aug 4.","pmid":"35924546","type":"DERIVED"}],"start_date":{"date":"2020-08-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","url":"https://clinicaltrials.gov/study/NCT04285086"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/surpass-et-nct04285086"}